Harrow, Inc. (NASDAQ:HROW) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its stake in Harrow, Inc. (NASDAQ:HROW) by 5.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,865 shares of the company’s stock after acquiring an additional 567 shares during the period. The Manufacturers Life Insurance Company’s holdings in Harrow were worth $248,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Harrow by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after acquiring an additional 21,253 shares in the last quarter. Woodmont Investment Counsel LLC raised its holdings in shares of Harrow by 73.3% during the first quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company’s stock worth $2,799,000 after purchasing an additional 89,510 shares during the period. Private Capital Management LLC raised its holdings in shares of Harrow by 7.8% during the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock worth $39,854,000 after purchasing an additional 217,896 shares during the period. Apis Capital Advisors LLC acquired a new stake in shares of Harrow during the second quarter worth $1,660,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Harrow by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock worth $1,843,000 after purchasing an additional 12,580 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on HROW. Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, October 4th. B. Riley reissued a “buy” rating and set a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Finally, Craig Hallum increased their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th.

Harrow Stock Up 1.9 %

HROW stock opened at $57.48 on Friday. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18. Harrow, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $59.23. The firm’s 50-day simple moving average is $44.27 and its 200 day simple moving average is $27.13. The stock has a market cap of $2.03 billion, a PE ratio of -63.16 and a beta of 0.75.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. The business had revenue of $48.94 million for the quarter, compared to analysts’ expectations of $42.78 million. As a group, sell-side analysts predict that Harrow, Inc. will post -0.14 EPS for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.